Karyopharm to Participate in Baird's Biotech Discovery Series

Karyopharm (Nasdaq: KPTI) announced that its senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m. ET.

Rhea-AI Summary

Karyopharm (Nasdaq: KPTI) announced that its senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m. ET.

Dr. Harrison is Professor of Myeloproliferative Neoplasms and Clinical Director at Guy's and St. Thomas' NHS Foundation Trust and is described as a leading international expert in myelofibrosis. A live webcast will be available under the company's Investor "Events & Presentations" page and will be posted for replay after the event.

Argus Dec 8 session

+2.43% close to close Open Argus

Details

News Market Reaction – KPTI

On Dec 8, the day this news came out, KPTI closed 2.43% above the previous close.

Data tracked by StockTitan Argus for the Dec 8 session.

Market Context

This announcement highlights Karyopharm’s participation in Baird’s Biotech Discovery Series, featuri...

Analysis

This announcement highlights Karyopharm’s participation in Baird’s Biotech Discovery Series, featuring a virtual fireside chat focused on myelofibrosis and related myeloproliferative neoplasms. It continues a pattern of conference visibility and investor communication rather than introducing new clinical or financial data. In light of prior disclosures around a $33.1M Q3 2025 net loss and going‑concern risks, investors may watch for how management frames trial progress, financing flexibility, and previously registered resales of up to 2,805,688 shares.

Key Figures

Event date: December 10, 2025 Event time: 12:00 p.m. ET

Event date

December 10, 2025

Date of Baird Biotech Discovery Series virtual fireside chat

Event time

12:00 p.m. ET

Scheduled start time for the virtual fireside chat

Historical Context

5 past events · Latest: Dec 01

5 events

1. Dec 01

   Inducement grants

   24h Move

   -6.8%

   Inducement stock options and RSUs granted to new hires under 2022 plan.

2. Dec 01

   Conference participation

   24h Move

   +2.3%

   Management fireside chat at Piper Sandler healthcare conference with webcast replay.

3. Nov 03

   Inducement RSU grant

   24h Move

   +4.7%

   Single-employee RSU inducement grant under Nasdaq Listing Rule 5635(c)(4).

4. Nov 03

   Earnings and pipeline

   24h Move

   +4.7%

   Q3 2025 results and progress, including SENTRY Phase 3 myelofibrosis enrollment.

5. Oct 27

   Earnings date notice

   24h Move

   +1.3%

   Announcement of Q3 2025 results date and related conference call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

myeloproliferative neoplasms, myelofibrosis

2 terms

myeloproliferative neoplasms medical

"Dr. Harrison is Professor of Myeloproliferative Neoplasms, Clinical Director..."

Myeloproliferative neoplasms are a group of blood cancers caused by the bone marrow producing too many of one or more types of blood cells, which can crowd out normal cells and impair blood flow. Investors pay attention because these conditions create clear medical needs and predictable markets for diagnostics, therapies and follow-up care—similar to a failing factory that creates demand for repair services and replacement parts—affecting drug development, regulatory milestones and potential sales.

myelofibrosis medical

"...and a leading international expert in myelofibrosis."

A bone marrow disorder in which healthy, spongy marrow is gradually replaced by scar tissue, like a garden soil turned to concrete so seeds can’t grow. That replacement reduces production of red and white blood cells and platelets, causing anemia, fatigue, infections and an enlarged spleen. Investors care because the condition creates demand for therapies, clinical trials and regulatory decisions that can materially affect drug sales and company valuations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., Dec. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m. ET. Dr. Harrison is Professor of Myeloproliferative Neoplasms, Clinical Director at Guy's and St. Thomas' NHS Foundation Trust and a leading international expert in myelofibrosis.

A live webcast of the event can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-in-bairds-biotech-discovery-series-302634110.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Karyopharm (KPTI) present at Baird's Biotech Discovery Series?

Karyopharm will present on Wednesday, December 10, 2025 at 12:00 p.m. ET.

Who from Karyopharm will participate in the December 10, 2025 fireside chat (KPTI)?

The company's senior management team and Dr. Claire Harrison will participate in the virtual fireside chat.

How can investors watch the Karyopharm (KPTI) webcast on December 10, 2025?

Watch the live webcast via the Investor "Events & Presentations" page at https://investors.karyopharm.com/events-presentations.

Will the Karyopharm (KPTI) fireside chat be available after the live event?

Yes. The webcast will be available for replay following the event on the same investor events page.

What is Dr. Claire Harrison’s role mentioned for the Karyopharm (KPTI) presentation?

Dr. Harrison is listed as Professor of Myeloproliferative Neoplasms and Clinical Director at Guy's and St. Thomas' NHS Foundation Trust and a leading expert in myelofibrosis.